Cellmids FGF5 inhibitor clinical study published
Filed with ASX · · 3 pages · English
Earlier from Anagenics
- Cellmid to Refinance R&D Loan Facility
- Cellmid: Appendix 4D and Half Year Accounts
- Midkine alopecia patent European allowance
- Cellmids usa midkine patent for alopecia allowed
- Appendix 4C
Later from Anagenics
- Nature Paper MK in Melanoma
- Cellmid secures premium US retail channel for evolis
- Cellmid completes US consumer study
- Cellmid receives $947K R&D tax credit
- Proposed consolidation of securities
Follow Anagenics into a list and get an email when it puts out news.
Follow Anagenics